VanEck Pharmaceutical ETF (PPH)
|Ex-Dividend Date||Oct 2, 2023|
|Day's Range||78.35 - 78.87|
|Inception Date||Feb 1, 2000|
About PPHFund Home Page
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is issued by VanEck.
Top 10 Holdings56.80% of assets
|Eli Lilly and Company||LLY||8.43%|
|Novo Nordisk A/S||NVO||6.61%|
|Johnson & Johnson||JNJ||6.14%|
|Novartis AG ADR||NVSN.MX||5.12%|
|Merck & Co., Inc.||MRK||4.92%|
|Oct 2, 2023||$0.3398||Oct 6, 2023|
|Jul 3, 2023||$0.3891||Jul 7, 2023|
|Apr 3, 2023||$0.6641||Apr 10, 2023|
|Dec 28, 2022||$0.240||Dec 30, 2022|
|Oct 3, 2022||$0.2696||Oct 7, 2022|
|Jul 1, 2022||$0.2496||Jul 8, 2022|
Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.
The XBI has been climbing this month. On Tuesday it jumped 5.4% to close at $70.91.
According to the latest CDC National Diabetes Statistics Report, more than 37 million people have diabetes in the U.S., or 11.3% of the population. The statistics for obesity are also dismal, as the W...
Ozempic commercials are, at this point, ubiquitous and while that's an anecdotal example, it also represents confirmation that obesity drugs are the next big thing in the pharmaceuticals industry.
Industry-leading pharmaceutical firms are adopting artificial intelligence (AI) to drive value for the future of their enterprise. AI is currently being implemented within the industry to reduce human...
For much of 2020 and 2021, the pharmaceutical stock investment thesis revolved around development and disbursement of coronavirus vaccines. While that made for an obvious catalyst, and a rewarding one...
The healthcare sector isn't setting the investment world ablaze this year, but it is outperforming the broader market, underscoring its defense posture.
This is a mid-term election year, meaning that some familiar issues investors should be aware of are popping up yet again. That includes reducing pharmaceutical prices.
Pharmaceuticals stocks and the related exchange traded funds are benefiting from the now-steady revenue stream provided by coronavirus vaccines, but with that priced into many pharmaceuticals equities...
Broadly speaking, the healthcare sector delivered some decent though not spectacular performances last year, with diversified exchange traded funds addressing the sector hindered by rough showings by ...
Pharmaceuticals stocks and the related exchange traded funds are turning solid performances in 2021. Investors looking for quality and growth traits might want to continue leaning on this corner of th...
Domestic dividend growth is on a torrid pace this year, and market observers expect that the trend will continue in 2022. Investors searching for sector and industry exchange traded funds with which t...
According to reports out Wednesday, the first U.S case of the Omicron variant of the coronavirus was discovered in California. More research is needed on the Omicron strain, but there's already ample ...
Blue-chip pharmaceuticals stocks are turning solid showings this year, but the group is lagging the broader market, indicating that some of the coronavirus vaccine blush is wearing off the group. Howe...
Healthcare stocks are solid but not spectacular performers. For example, the S&P 500 Health Care Index is higher by more than 17%, though that lags the broader market.
There are multiple coronavirus vaccines on the market, and with the likelihood of booster shots increasing by the day, the revenue outlook for healthcare exchange traded funds, including the VanEck Ve...
Biogen's (NASDAQ: BIIB) Aduhelm sparked a rally in the biotech giant's share price and hope that progress is being made in treating Alzheimer's. However, the news isn't free of controversy, and carrie...
The pharmaceuticals industry got a boost last year when a Covid-19 vaccine was introduced, but artificial intelligence (AI) could keep the sector and ETFs like the VanEck Vectors Pharmaceutical ETF (P...
Coming off a vaccine rally that started in the middle of 2020, the pharmaceutical industry will continue to evolve as technological advances make their way into the sector, which should help ETFs like...
With 2020 election season in the rearview mirror, it could be a great time to revisit health and pharmaceutical ETFs, including the VanEck Vectors Pharmaceutical ETF (NASDAQ: PPH). PPH tracks the MVIS...
After scuffling amid political uncertainty leading up to Election Day, pharmaceutical stocks and exchange-traded funds are finally perking amid a spate of encouraging news regarding coronavirus vaccin...
By VanEck Hope Springs Eternal Hopes of a return to normality are increasing after a year of pandemic-induced tumult. News that COVID-19 vaccines developed by Pfizer and BioNTech, and Moderna were mor...
Investors looking for compelling valuations don’t have to go deep into the lagging value factor. They can harness some growth with pharmaceuticals ETFs, including the VanEck Vectors Pharmaceutical ETF...